University of Hawai‘i at Manoa Homepage


Ali Naderi, MD, CCST (UK)

Ali Naderi, MD, CCST(UK)
  • Associate Member
    Cancer Biology Program
    University of Hawaii Cancer Center
  • Academic Appointments

  • Associate Researcher (Associate Professor)
    University of Hawaii Cancer Center
    University of Hawaii at Manoa


  • Doctorate in Medicine and Biomedical Sciences (MD) Shahid-Beheshti University of Medical Sciences, Tehran
  • Residency (Internal Medicine) Wayne State University, Michigan University of Maryland, Baltimore
  • Specialist Certification (CCST in Medical Oncology) The Medical Royal Colleges, United Kingdom
  • Diplomate (Medical Oncology) American Board of Internal Medicine
  • Fellowship (Medical Oncology) Mayo Clinic, Minnesota
  • Postdoctoral Research Fellowship (Cancer Biology) University of Cambridge, United Kingdom

Research Focus

Dr. Naderi is a physician-scientist and medical oncologist with a focus on breast cancer research. Dr. Naderi joined the University of Hawaii Cancer Center in January 2016 and previously held academic positions at the University of Iowa and University of Queensland. Dr. Naderi currently has research projects to study the molecular functions of Androgen Receptor (AR) and Prolactin-Induced Protein (PIP).

PIP is one of the most abundant proteins expressed in breast cancer and is used as a characteristic biomarker in the diagnosis of this disease. Dr. Naderi's laboratory has demonstrated that PIP has a significant function in the cell cycle progression of breast cancer cells and his group currently studies the molecular mechanisms of PIP function and translational applications of this widely expressed protein in breast cancer. Furthermore, Dr. Naderi's laboratory was one of the first to identify the role of AR signaling in Estrogen Receptor-negative tumors and contributed to the characterization of "molecular apocrine" subtype of breast cancer using functional and genomic studies. In this respect, Dr. Naderi's group currently studies the AR transcriptional network to discover novel AR target genes and coregulators in breast cancer. Dr. Naderi is also interested in the therapeutic implications of AR inhibition in the management of breast cancer patients.

Selected Publications

  • Naderi A. (2017). C1orf64 is a novel androgen receptor target gene and coregulator that interacts with 14-3-3 protein in breast cancer. Oncotarget, DOI: 10.18632/oncotarget.17826. PMID: 28571002.
  • Naderi A. (2015). Coagulation factor VII is regulated by androgen receptor in breast cancer. Experimental Cell Research, 331(1): 239-250.
  • Naderi A, Vanneste M. (2014). Prolactin-Induced Protein is required for Cell Cycle Progression in Breast Cancer. Neoplasia,16(4): 329-342.e14.
  • Naderi A, Meyer M. (2012). Prolactin-Induced Protein mediates cell invasion and regulates Integrin signaling in estrogen receptor-negative breast cancer. Breast Cancer Research, 14(4): R111.
  • Naderi A, Meyer M, Dowhan DH. (2012). Cross-regulation between FOXA1 and ErbB2 signaling in estrogen receptor-negative breast cancer. Neoplasia, 14(4): 283-296.
  • Naderi A, Liu J, Francis GD. (2012). A feedback loop between BEX2 and ErbB2 mediated by c-Jun signaling in breast cancer. International Journal of Cancer, 130(1): 71-82.

Publication list via PubMed